Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
New IHS Markit Animal Health report reveals companion
animals is fastest growing product sector
The animal health industry encompasses a broad spectrum of
products used to prevent, control and treat diseases to ensure the
health and productivity of animals.
Access your free sample pages from our Top 20 Animal Health
Products report.
In 2019, the Top 20 Animal Health Products
generated estimated sales of US$6.7bn from parasiticides and
dermatological agents for companion animals and antimicrobials and
immunological products for livestock animals.
Over the past decade, companion animal has been the fastest
growing sector representing 75% of total Top 20 animal health sales
in 2019.
Parasiticides, the largest product group continues to feature
leading brands such as Advantage, Frontline, Heartgard and
Revolution within the Top 10 animal health products. This segment
has also had a number of new product introductions. Most notable
are the chewable parasiticides from the new isoxazoline chemical
class (Bravecto, Nexgard, Simparica and Credelio) and Seresto an
antiparasitic collar providing protection for up to eight
months.
The most significant innovation in the companion animal sector
has been the introduction of Apoquel and Cytopoint from Zoetis for
the treatment of atopic dermatitis in dogs. Cytopoint is the first
monoclonal antibody to enter the animal health industry and more
biological therapies are likely to follow.
A powerful trend reshaping the companion animal health market is
"humanisation of pets" whereby they have become a family member.
Pet owners are actively seeking to improve the wellbeing and
longevity of their pets. This coupled with insights from pet
wearable smart technology and more rapid diagnostic testing is
fuelling innovation into targeted therapies to meet market needs.
Products treating age related diseases will edge their way into the
Top 20, such as treatments for osteoarthritis and pain e.g. Zoetis'
Librela and Elanco's Galliprant.
Animal health products to treat infectious diseases in livestock
are important to ensure the safe supply of affordable food.
Vaccines are the most cost-effective strategy for preventing
infectious diseases. However, there are not always vaccines to
prevent all infections and therefore emerging diseases such as
African swine fever (ASF) have had devasting impact on the
livestock industry and the broader economy.
Therefore, such disease outbreaks and concerns about
antimicrobial resistance has prompted further efforts into vaccine
development. Although use of antibiotics to treat infections is
likely to continue on a controlled scale, the animal health
industry is expected to move away from antibiotics towards
vaccines.
The frequency and impact of new and re-emerging diseases is
likely to grow as farms get larger and international trade
continues to increase. Besides developing vaccines, the industry is
also embracing technological advancement to improve productivity,
welfare and management of livestock.
Over the last decade major animal health companies have made
acquisitions to build a portfolio of preventative technologies.
This includes surveillance systems and sensor technologies that
capture data on individual animals with the potential to detect
diseases before they spread.
Also rapid on-farm diagnostic testing that can identify specific
pathogen are being developed. In addition, the use of microbiome to
improve gut health and potentially boost immune systems in animals
represent tremendous potential in the livestock industry.
The animal health industry is going through a technological
revolution delivering solutions beyond treatment options. The speed
at which these digital technologies are adopted across both
livestock and companion animal sectors will continue to accelerate
with new technologies emerging to improve health and productivity
of animals.
Methodology
This report is based on desk research using a variety of public
information, IHS internal database and other publications that are
provided in the references.
The leading animal health product were identified through IHS
internal knowledge and company annual reports. Some of the animal
health companies report individual sales of their top-selling
products, others provide a total and some provide no information.
Therefore, this list of the Top 20 animal health products is based
on reported sales and best estimations.
The sales of the Top 20 products are presented in US dollars.
Some of the companies report annual sales in US dollars and others
in euros. This report provides a ranking of the Top 20 products in
US dollars, therefore euro reported sales were translated into US
dollars using the exchange rate from the Federal Reserve Bank of
St. Louis.
Each of the Top 20 products were profiled to gain a deeper
understanding into the life cycle management of the brand in the
main markets of the US and EU. This was determined by following the
brands regulatory status and development in these markets. In the
US regulatory agencies for animal health therapies include the US
Department of Agriculture (USDA), Environmental Protection Agency
(EPA) or the Centre for Veterinary Medicine (CVM), that is part of
the FDA.
The USDA reviews applications for new animal vaccines and
biologicals, the EPA accesses pesticide compounds used for animal
health and the CVM small molecules and other animal health drugs.
In the EU, animal health products are regulated via a centralised
process through the European Medical Agency (EMA). It should be
noted that in Europe products can also be approved via a
decentralised process at a country level and these are not included
in the report.
Contents
Chapter 1 is the executive summary.
Chapter 2 outlines the Top 20 animal health products ranked by
sales in 2019 and analyses these products by key segments companion
animals and livestock animals.
Chapter 3 discusses the leading products by companies.
Chapter 4 profiles the Top 20 products.
Author
Amita Barnish is a market analyst and report writer. She
graduated with a BSc (Hons) degree in Applied Chemistry from the
University of Kingston and an MBA from the Swiss Business School.
She has over 25 years of experience performing market and
competitor analysis across multiple industries: agribusiness,
pharmaceutical and biotechnology.
